JDRF (The Juvenile Diabetes Research Foundation)

Diamyd Medical AB is a Swedish biotechnology company focused on developing therapies for autoimmune diabetes. The company is advancing its lead product, Diamyd, an antigen-specific immunomodulating vaccine designed for the treatment of type 1 diabetes and latent autoimmune diabetes, which is currently in Phase IIb clinical development. Additionally, Diamyd Medical is working on Remygen, an oral regenerative and immunomodulatory drug candidate aimed at treating autoimmune and type 2 diabetes, now in Phase I/II clinical trials. The company also leverages its GABA technology, which is integral to its proprietary drug product development. Founded in 1984 and located in Stockholm, Sweden, Diamyd Medical was previously known as Diamyd Therapeutics AB until its name change in April 2013.

Tidepool is a nonprofit organization dedicated to improving the lives of individuals with insulin-requiring diabetes by providing accessible and actionable diabetes data. The company offers a platform that integrates data from various diabetes devices, facilitating better decision-making and enhancing diabetes management. Through its innovative approach, Tidepool liberates data, allowing users and their care teams to gain insights and context for managing their condition effectively. The platform is designed to be user-friendly, enabling individuals to share their data easily and make informed decisions about their health. By leveraging technology, Tidepool aims to empower diabetes patients to achieve optimal health outcomes.

Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, dedicated to leveraging the body's natural biology to repair or reverse damage from various degenerative diseases. The company employs a unique Progenitor Cell Activation approach, utilizing combinations of small molecules to stimulate progenitor cells to regenerate functional tissue. Its lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at addressing the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is developing therapies for a variety of degenerative conditions, including multiple sclerosis and ailments affecting muscle, skin, gastrointestinal tract, and bone health. The company has also established a collaboration agreement with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics is focused on disease modification through innovative therapeutic strategies.

Zucara Therapeutics Inc. is focused on developing innovative therapeutics aimed at preventing hypoglycemia in patients with diabetes. Founded in 2014 and based in Toronto, Canada, with an additional office in Vancouver, the company is working on a once-daily treatment that targets somatostatin type 2 receptors in the pancreas. This pre-clinical therapy aims to regulate hormone levels that are often uncontrolled in Type 1 diabetes, thereby preventing dangerous drops in blood sugar and restoring natural glucose levels. Zucara's approach offers a significant advantage over existing treatments, which typically only address hypoglycemia after it occurs, thereby enhancing diabetes management and improving patient outcomes. The therapeutic is designed to be administered via subcutaneous injection, addressing the serious health risks associated with low blood sugar episodes.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, focused on developing innovative cell replacement therapies for diabetes. The company is working on several product candidates, including VC-01, designed for type 1 diabetes, and VC-02, which facilitates blood vessel interaction with implanted pancreatic precursor cells. Their VCTX210 product utilizes a proprietary human stem cell line that helps prevent immune system rejection, eliminating the need for immunosuppressants. ViaCyte's therapies differentiate stem cells into pancreatic beta-cell precursors that are implanted in an encapsulation device, enabling the production of insulin in response to blood glucose levels. The company's aim is to provide long-term solutions for both type 1 and type 2 diabetes patients, reducing their dependence on insulin and minimizing associated health complications. Founded in 1999 and formerly known as Novocell, Inc., ViaCyte also has operations in Athens, Georgia.

AnTolRx, Inc. is a biotechnology company based in Boston, Massachusetts, established in 2015. The company specializes in developing novel nanoparticle-based therapies aimed at treating autoimmune diseases. AnTolRx's innovative approach seeks to address the limitations of traditional therapies that broadly suppress the immune system and can lead to severe side effects, such as infections and tumors. Instead, AnTolRx focuses on selectively targeting pathogenic immune cells to provide a unique tolerogenic signal, promoting antigen-specific immune tolerance. This method aims to induce an anti-inflammatory response, enhancing treatment efficacy and safety for conditions such as type 1 diabetes, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Through its proprietary drug development process, AnTolRx aspires to meet the clinical need for targeted immune regulation while minimizing adverse effects.